AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03517943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study NCT03517943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-SAG)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study NCT03517943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study NCT03517943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Loratadine + Pseudoephedrine sulfate (Claritin-D, BAY818725) (Manufacturer-Heist)
Description: Oral, Loratadine 5 mg/ pseudoephedrine sulfate 120 mg (x1)
Study NCT03592043 — intervention group
Intervention type: DEVICE
Intervention: MitraClip
Description: Transcatheter Mitral Valve Repair with MitraClip
Study NCT04020315 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Non-surgically performed scaling and root planing
Description: Non-surgically performed scaling and root planing
Study NCT06341777 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Audio-visual training (AVT) telerehabilitation
Description: Participants are trained at home, with remote supervision, for 3 weeks (5 days/week, 2 hours/day) using an audio-visual device suitable for telerehabilitation (AVDESK, Linari Medical). Specifically, visual stimuli (LEDs) appear on a semicircular panel, either alone or paired with an acoustic cues, at different eccentricities. Stimuli to the blind visual field (70%) and intact visual field (30%) are presented in random sequence. Patients are trained to scan the visual field by shifting their gaze (from the central fixation point) towards the visual target (with or without sounds), without head movements, and to report its presence by pressing the response key.
Study NCT03633292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiseptic clorhexidine gel (Lacer, Barcelona, Spain)
Description: Together with the dispensing container, the dosing and dosage of the gel in research will be attached, with the description of the pharmaceutical form, packaging and labeling of the product. Packages with 8 ml of the gel under investigation, sufficient treatment for 1 month of applications. Posology: After tooth brushing, apply a small amount of gel on the fingertip of a freshly washed finger and spread it over the gum, doing a gentle massage, for 15 , 2 times a day after proper oral hygiene and it is recommended not to ingest no liquid or food until after half an hour of use.
Study NCT03633292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Master formula of aloe vera gel 80%
Description: Blindly and in the same container as chlorhexidine, patients will be instructed to apply aloe vera gel on the gums and mucous membranes once the orthodontic appliances have been cemented
Study NCT02296658 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: intensity-modulated radiotherapy
Description: A total irradiation dose of 45 Gy was delivered in daily 1.8-Gy fractions (5 days a week over 5 weeks) to all patients.
Study NCT02296658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1,80mg/m2/d,peroral BID,in treatment days concurrently with intensity-modulated radiotherapy.
Study NCT02212119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Botulinum Toxin
Study NCT02212119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Study NCT02652637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: neomycin, metronidazole, polyethylene glycol (PEG)
Study NCT01076543 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01076543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study NCT01076543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study NCT01905618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Web-based curriculum on tobacco dependence treatment
Description: The University of Massachusetts Medical School's web-based course, Basic Skills for Working with Smokers was adapted for this Randomized Controlled Trial (RCT). The goal is to provide standardized information in the following core tobacco content areas: epidemiology of tobacco use, health consequences of tobacco use, nicotine dependence and withdrawal assessment, and provision of behavioral and pharmacotherapy tobacco treatment. The course is 3 hours in length and can be completed at the student's convenience. The dean and the course director at each medical school required that the first year medical students complete the web-based curriculum prior to the next component of the study, the role play.
Study NCT01905618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tobacco Counseling Role Play
Description: The goal of the role play is to provide each student with the opportunity to apply what he/she learned in the web-based curriculum (the 5 As and the physician delivered intervention approach). The one hour session begins with a video of a patient-centered counseling approach which incorporates the 5A intervention presented in the web-based course. This is followed by a 30 minute role play session including various scenarios with physician/patient interaction. Students role play either as physician, patient or observer for each scenario.
Study NCT01905618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Preceptor Training and Teaching Medical Students
Description: The goal of this intervention is to train preceptors in the use of the 5As with their patients and to teach and motivate their medical students to use the 5As. The academic detailing approach is used to provide a standardized 30 to 45 minute group training session during the third year clerkship. All preceptors and medical students are encouraged to intervene with patients who smoke. Preceptors are encouraged to model the 5As, observe and give feedback to the medical student in its use. Study-tailored handouts are available for preceptors and students. This component is implemented with the study cohort in their third year of medical school.
Study NCT01905618 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Booster Session
Description: The last component of the intervention, a small group booster session, occurs during the third year of medical school. A five minute video reviews the use of the 5As and patient-centered counseling strategies. Faculty facilitate a small group discussion after viewing the video.
Study NCT03502538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Curaprox 5460 Ultra Soft
Description: The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
Study NCT03502538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Curaprox 5460 Ultra Soft
Description: The toothbrush Curaprox 5460 Ultra Soft will be the tested toothbrush model, in order to asses its efficacy in plaque removal. Therefore, the study participants should brush their teeth using this toothbrush model, following the instructions of the investigator. From the data collect related in plaque removal the results will be arrived at.
Study NCT03502538 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oral-B Indicator Plus
Description: Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
Study NCT03502538 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Oral-B Indicator Plus
Description: Following the same method of the Curaprox group intervention, the participants should brush their teeth using the Oral-B Indicator Plus toothbrush and based on the data collect, the results will be compared with the first group of intervention.
Study NCT03119597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Wild Blueberry Powder-13g
Description: Formulation containing approximately 250mg of anthocyanin+ 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
Study NCT03119597 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Formulation containing approximately 4.79g Fructose+ 4.52g Glucose+ 45mg Vitamin C
Study NCT03601169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low Dose MMFS-205-SR
Description: Twice daily, oral 500mg tablets
Study NCT03601169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Dose MMFS-205-SR
Description: Twice daily, oral 500mg tablets
Study NCT03601169 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Twice daily, oral
Study NCT01630135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate
Description: 55 mcg/day, intranasal, 2 weeks
Study NCT01630135 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, intranasal, 2 weeks
Study NCT02435303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sildenafil
Study NCT02435303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02554760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The ZELTIQ CoolSculpting System
Description: The CoolSculpting device and CoolCore applicator with and without the Crown Cooling Insert will be used to perform the treatments.
Study NCT03647566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: 18F Sodium Fluoride Positron Emission Tomography / Computed Tomography
Description: PET scan using the 18F-Sodium Fluoride radiotracer followed by an attenuation correction CT scan
Study NCT02037477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vonoprazan
Description: Vonoprazan tablets
Study NCT03647566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: CT Aortic Angiogram
Description: CT scan to assess aortic morphology and contextualise PET scan
Study NCT03647566 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Aortic MRI
Description: Aortic MRI to assess aortic morphology and contextualise PET scan
Study NCT00757393 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D + Calcium + Exercise program
Description: Subjects is this arm of the study will receive a) a supplementation with vitamin D3, 1000 IU daily b) a dietary calcium intake set at DRI for age and a supplement used as needed to meet the requirement and c) a weight bearing exercise program appropriate for the underlying medical condition
Study NCT00757393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vitamin D + Calcium + Exercise program + Humatrope
Description: Subjects in this arm will receive the same as those in arm 1 as well as Humatrope by subcutaneous infection 7 days a week at a dose of 0.05 mg.kg/day.
Study NCT02553343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose quadrivalent influenza virus vaccine
Description: 0.5 mL, Intramuscular (IM), injected into the deltoid area
Study NCT02553343 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: High-dose influenza virus vaccine
Description: 0.5 mL, Intramuscular (IM), injected into the deltoid area
Study NCT02553343 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: High-dose trivalent inactivated influenza vaccine
Description: 0.5 mL, Intramuscular (IM), injected into the deltoid area
Study NCT02793765 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT02793765 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sipuleucel-T
Study NCT01579513 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methylprednisolone
Description: Methylprednisolone at a dose of 30 mg/kg body weight and a concentration of 62.5 mg/cc. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
Study NCT01579513 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline will be drawn up in an identical volume to that needed for active study drug. The study drug will be delivered in a blinded fashion to the anesthesiologist and will be administered intravenously with the induction of anesthesia.
Study NCT01136577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Phototherapy
Description: Phototherapy devices of ramp type placed over the incubator to treat with light in the 420-490nm range one face of the naked baby suffering jaundice.
Study NCT03217552 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Mologic Biomarker Panel
Description: In brief the proposed biomarkers will be measured in the laboratory of Mologic . These will initially be performed using standard lab assays (Enzyme Linked Immunosorbent Assays, ELISA). Biomarkers that show promise will then be mounted on a novel lateral flow device (under development), that could ultimately be deployed at the patients bedside.
Study NCT02361034 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GRC 27864
Study NCT02361034 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02205372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-3995
Study NCT02205372 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03185286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3d-printed personalized metal implant
Description: 3d-printed personalized metal implant will be used in subtalar arthrodesis.
Study NCT01623921 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: standard care treatment
Description: Group 1: control :(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Study NCT01623921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Celecoxib
Description: Celecoxib 200 mg × 2/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Study NCT01623921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosuvastatin
Description: Rosuvastatin 40mg × 1/d+:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Study NCT01623921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Combined therapy
Description: Combined therapy with Celecoxib 200 mg× 2/d + Rosuvastatin 40× 1/d +:(standard care treatment for individual lung contusion inluding analgesia with paracetamol/dypiron/ tramal)
Study NCT02958579 — intervention group
Intervention type: OTHER
Intervention: No intervention will be done. Participants are on standard care and the treatments will be recorded because of observational nature of this study.
Study NCT04505852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Embrace
Description: Patients wear Embrace2 to help in seizure reporting and patient care.
Study NCT01031303 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTacP-IPV combined vaccine (TETRAXIM™)
Description: 0.5 mL, Intramuscular
Study NCT02415543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SIL-TEP Inguinal Hernia Repair
Description: perform the laparoscopic total extraperitoneal inguinal hernia repair using a single incision
Study NCT02415543 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: TEP Inguinal Hernia Repair
Description: perform the multiport laparoscopic total extraperitoneal inguinal hernia repair
Study NCT02996916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olmesartan
Description: 10-40mg daily
Study NCT02996916 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amlodipine
Description: 2.5-10mg daily
Study NCT01289886 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: BR-A-657
Description: 20, 60, 120, 240, 360, 480mg or placebo tablet
Study NCT02037477 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: Esomeprazole capsules
Study NCT03003247 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDP-120 Gel
Description: IDP-120 Gel is a combination product
Study NCT03003247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP 120 Component A Gel
Description: Monad of Component A
Study NCT03003247 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IDP 120 Component B Gel
Description: Monad of Component B
Study NCT03003247 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: IDP 120 Vehicle Gel
Description: Vehicle
Study NCT03421964 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Resilience/Adjustment Counseling
Description: The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions. The RAI will be implemented by experienced, licensed therapists.
Study NCT03421964 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resilience/Adjustment Counseling with Booster Sessions
Description: The Resilience and Adjustment Intervention (RAI) consists of seven 60-minute sessions scheduled over seven weeks. Before the first session, participants will be mailed an empty loose-leaf binder to store and organize completed self-assessments, reading materials, and homework assignments from each session. They will be asked to review materials and complete worksheets between sessions.~For the RAI+ participants, three booster sessions will be implemented. The three weekly booster sessions will be scheduled to start three months following completion of Session 7 of the RAI. The program will be implemented by experienced, licensed therapists.
Study NCT01436487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MultiStem
Description: single infusion 1-2 days following ischemic stroke
Study NCT01436487 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: single infusion 1-2 days following ischemic stroke
Study NCT02727049 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative medicine (OMM)
Description: Osteopathic manipulative medicine includes all types of manual therapies to gently restore and/or optimize one's natural joint, muscle, and other soft tissue balance.
Study NCT01614015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supervision
Description: SAU consists of a 1-hour weekly group supervision session with the clinical team (typically 3-6 therapists). The on-site supervisor also conducts individual supervision sessions with each member of the clinical team. As such, the usual FFT supervision practice involves each therapist receiving two hours of supervision per week (one hour of group, one hour of individual). Supervision sessions are conducted by an on-site supervisor who has received intensive training in FFT supervision. The on-site supervisor also continues to receive feedback and guidance from a national consultant (FFT LLC) for one hour per month.
Study NCT01614015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Observational Supervision
Description: One intent of BOOST is to provide ongoing development of therapist clinical skills, and identify novel approaches to unique family circumstances that are consistent with FFT treatment. BOOST involves the BOOST supervisor reviewing the recorded therapy sessions prior to supervision sessions with the therapist and on-site FFT supervisor and weekly group and/or individual supervision meetings during which the BOOST supervisor provides feedback and coaching to the therapist. The goal of observation-based supervision is to ensure feedback to therapists is based on the supervisors' direct judgments about therapist behaviors, model adherence, and delivery of FFT services rather than relying solely on therapist self-report of session activities and interactions.
Study NCT03094585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written and oral information
Description: The written information (booklet) was 12 A4 pages long and took about 15 minutes to read. The oral information consisted of group sessions which focused on active feedback. Each session was lead by one of the authors who first went through the topics described in the booklet. The review of the topics was followed by a plenary discussion.
Study NCT03094585 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Written information
Description: The written information (booklet) was 12 A4 pages long and took about 15 minutes to read.
Study NCT04609657 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: Beverage
Study NCT04609657 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flavored carbonated soft drink (CSD)
Description: Beverage
Study NCT02782741 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avalglucosidase alfa (GZ402666)
Description: Pharmaceutical form: powder for concentrate for solution for infusion Route of administration: intravenous